Evaluate the Effect of Entrectinib on the Pharmacokinetics of Midazolam in Cancer Patients

Completed · Phase 1

Conditions studied: Advanced Solid Tumor

In brief

This is an open-label study in advanced solid tumor patients to determine if entrectinib affects the pharmacokinetics of midazolam and any of its pharmacologically active metabolites.

Key facts

Study ID

NCT03330990

Run by

Hoffmann-La Roche

People needed

15

Starts

2017-11-14

Expected to finish

2018-07-11

Last updated by the study team

2018-08-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must meet the following criteria in order to be included in the research study:
• Histologically or cytologically confirmed diagnosis of advanced or metastatic solid tumors that are not responsive to standard therapies or for which there is no effective therapy.
• At least 2 weeks or 5 half-lives, whichever is shorter, must have elapsed after prior chemotherapy or small molecule targeted therapy, respectively, at the time of the start of midazolam administration.
• Eastern Cooperative Oncology Group (ECOG) Performance Status score of ≤1.
• Adequate hematologic, liver and renal function.
• Ability to understand the nature of this study and give written informed consent.

You may not qualify if…

• Patients who meet any of the following criteria will be excluded from study entry:
• Participation in another therapeutic clinical trial within 28 days prior to start of midazolam administration.
• Prior treatment with entrectinib.
• Known hypersensitivity or intolerance to midazolam or oral formulation excipients, including allergy to cherries.
• Any condition (in the past 3 months) that may interfere with the conduct of study assessments or may interfere with the interpretation of study results.
• History of non-pharmacologically induced prolonged QTc interval (e.g., repeated demonstration of a QTc interval > 500 milliseconds from ECGs).
• Known active infections that may interfere with the conduct of study assessments or may interfere with the interpretation of study results (bacterial, fungal, or viral, including human immunodeficiency virus positive).
• Other Protocol defined Inclusion/Exclusion criteria apply.

Where it is running

• SCRI-Denver Drug Development Program — Denver, Colorado, United States
• Florida Cancer Specialists - Sarasota (North Catttlemen Rd) — Sarasota, Florida, United States
• Tennessee Oncology — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.